Premiere Oncology conducts Phase 1, 2 and 3 clinical trials. We offer a wide array of studies for the treatment for all advanced malignancies. We work collaboratively with clinicians across the country to provide their patients with innovative treatments that bridge the gap between established and future therapies. Sponsors with which we have worked include: Amgen, Amplimed, Antigenics, ArQule, Astra Zeneca, Attenuon, Biogen IDEC, Beohringer-Ingelheim, Bristol Myers Squibb, CancerVax, CovX, Dynavax, Eisai, Exelixis, Genentech, Hana Biosciences, Infinity Pharmaceuticals, Kosan, Nektar, Neopharm, Novacea, Peregrine, Pfizer, Raven, Sanofi-Aventis, SGX, SuperGen, Synta, Tempol, Taiho, Tracon, Wyeth, and Ziopharm. These relationships help to ensure that Premiere Oncology has access to the most exciting products being developed for the treatment of cancer.

Lee S. Rosen, MD has a reputation for excellence in the conduct of early stage clinical trials for patients with solid tumors and treatment of patients with gastrointestinal malignancies.  He received his B.A. in English Literature from Yale University, a Masters of Public Policy (M.P.P.) from Harvard University's John F. Kennedy School of Government and his Medical Degree from Baylor College of Medicine in Houston, Texas.

Dr. Rosen is a principal investigator for many clinical trials focusing on new cancer drug development (Phase 1).  Formerly Assistant Professor in the Division of Hematology-Oncology, Department of Medicine at the University of California, Los Angeles (UCLA), he founded the Developmental Therapeutics Program, a cancer research initiative focused on new drug development.  Dr. Rosen has made significant contributions to translational research with angiogenesis inhibitors (a new class of drugs developed to treat cancer by inhibiting development of new blood vessels), signal transduction inhibitors and innovative drug combinations. 

As a result of his Phase 1 experience, Dr. Rosen has developed skills pertinent to the treatment of thyroid cancer, sarcomas, and other rare solid tumor types that do not have United States Food and Drug Administration (FDA) approved treatments available.  He has led pivotal clinical trials of many products subsequently approved by the FDA for the treatment of cancer including Camptosar (irinotecan HCL injection), Eloxatin (oxaliplatin), Zometa (zoledronic acid for injection) and Sutent (sunitinib malate).  In the year 2000, his work with angiogenesis inhibitors was featured on the CBS television program 60 Minutes.  He has since treated hundreds of patients with more than a dozen drugs in this class. 

Linnea Chap, MD is a highly respected specialist in cancers affecting women. She received her medical degree from the University of Chicago, completed her residency in internal medicine at Northwestern Memorial Hospital and her fellowship in both Hematology and Medical Oncology at UCLA. She joined the faculty at UCLA in 1995 serving most recently as Associate Professor of Medicine and co-director of the UCLA/Revlon Multidisciplinary Breast Center, overseeing the Multidisciplinary Breast Clinic. Dr. Chap has multiple publications to her credit and has led several breast and ovarian cancer treatment protocols, including the pioneering use of novel biologic agents such as Herceptin and Avastin.

In 2001, Dr. Chap was named one of "America's Top Breast Cancer Doctors" by Redbook, a national women's magazine. Annually, she has also been listed as one of "America's Top Doctors for Cancer". Recognized for her teaching and speaking skills, Dr. Chap has a national reputation where she is frequently called on to relate the most recent advances in breast cancer treatment.

Jonathan Goldman, MD graduated magna cum laude from Harvard University and received his medical degree from Stanford University. He completed his residency in internal medicine at University of California San Francisco and his fellowship in both hematology and medical oncology at UCLA.

In addition to seeing all types of hematology and oncology patients, Dr. Goldman will be developing a multidisciplinary thoracic malignancy program in our community.

Premiere Oncology's research staff has a cumulative total of more than 50 years' experience in clinical research, including contracts, budget development, study coordination, and data management.

Oncology